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CHAPTER 7 
The Denver-Pittsburgh Liver Transplant Series 
ROBERT D. GORDON, SHUNZABURO IWATSUKI, ANDREAS G. TZAKIS, 
CARLOS O. ESQUIVEL, SA TORU TODO, LEONARD MAKOWKA, 
THOMAS E. STARZL 
The Department of Surgery 
University of Pittsburgh 
Pittsburgh, PA. 
The liver transplant program at the University of 
Colorado began using CsA in 1980 and it soon became 
apparent that the most effective way to use the drug 
was in combination with low-dose steroids (1). The 
Starzl program transferred in 1981 to the University of 
Pittsburgh where it, along with programs in kidney and 
heart tr:ansplantation, has flourished (Fig. 1). In 1984, 
use of monoclonal murine antihuman lymphocyte an-
tibody (Orthoclone OKT3[R]) was begun in trials in Pitts-
burgh for treatment of steroid-resistant rejection and im-





sity of Pittsburgh. The liver transplant 
program has become the most active clinical 
transplant program at the medical center but 
there has also been substantial growth in the 
kidney and heart transplant programs. 
On July 20, 1987, the 1,000th primary human liver 
transplant in the Denver-Pittsburgh CsA series was per-
formed. The results of this experience were recently 
presented by Iwatsuki at the International Transplant 
Forum held in Pittsburgh to honor 25 years of contribu-
tions to this field by Thomas E. Starzl. The full proceed-
ings of the forum will be published in Transplantation 
Proceedings. Highlights of this 1,000-case experience 
are presented here. 
SURVIVAL AFTER LIVER TRANSPLANTATION 
Most of the morbidity and mortality after liver 
transplantation occurs within the first year after 
transplantation. Routine use of CsA has had a dramatic 
impact on survival during this critical period. One-year 
survival after liver transplantation has improved from 
32.4% with azathioprine and high-dose steroids to 
70.5% with esA and low-dose steroids (Fig. 2). 
Equally impressive has been the durability of liver 
grafts beyond the first year after transplantation. Only 
55 of the original 170 patients transplanted in Denver 
using azathioprine and high-dose steroids survived at 
least one year, but 28 of these 55 remain alive and well, 
including 20 patients more than 10 years after 
transplantation. Even more remarkable is the fact that 
of 498 patients transplanted with GsA-prednisone who 
survived at least one year, only 33 have subsequently 
been lost. 
Biliary atresia, inborn errors of metabolism, and 
postnecrotic or cryptogenic cirrhosis have been the 
most common indications for transplantation in children 
(Table 1). In adults, the most frequent indications for 
liver transplantation are postnecrotic cirrhosis, primary 
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biliary cirrhosis, and sclerosing cholangitis (Table 1). 
Survival rates for these indications are similar and are 
summarized in Figures 3 and 4. 
Recurrence of Disease 
Liver cancer 
Transplantation for most forms of primary liver can-
cer has proven disappointing (4). For all but a few 
types of liver cancer, recurrence of cancer has been 
common within one year after transplantation. Patients 
with epithelioid hemangioendothelioma have generally 
done well as have patients with small incidental 
hepatocellular cancers discovered at transplantation for 
other liver disorders such as postnecrotic cirrhosis or 
tyrosinemia. Patients with the fibrolamellar variant of 
hepatocellular cancer have tended to have the longest 
palliation after transplantation, sometimes lasting 
several years. However, most patients with hepatocel-
lular cancer too extensive for conventional resection 
and patients with bile duct cancers have benefited little 
if any from transplantation. 
Of the 83 patients transplanted for sclerosing cholan-
gitis, 75 had no evidence of bile duct cancer complicat-
ing their disease and 57 of these patients survive. One-
year actuarial survival for patients with benign disease 
is 80.2%. Eight patients were transplanted and found to 
have malignant bile duct lesions in the resected liver. 
Only 3 patients have survived and one-year actuarial 
survival for patients with malignant disease is only 
33.3% (p<0.02). 
Table 1. Major indications for liver transplantation. 
Indication Pediatric 
Cirrhosis 40 (12.0%) 
Biliary Atresia 178 (53.3%) 
Primary biliary cirrhosis 0 
Inborn errors 63 (18.9%) 
Sclerosing cholangitis (0.3%) 
Primary liver tumors 4 (1.2%) 
Fulminant hepatic failure 13 (3.9%) 
Secondary biliary cirrhosis 7 (2.1%) 
Familial cholestasis 15 (4.5%) 
Budd-Chiari syndrome 2 (0.6%) 
Congenital hepatic fibrosis 7 (2.1%) 
: ................. , .................. esA (n=1000) 
Azathioprine (n=170) 
rates 
transplanted with azathioprine - high-dose 
steroids between March 1963 and February 
1980 and for 1, 000 patients transplanted with 
GsA- low-dose prednisone between March 
1980 and July 1987. Follow-up is complete 
through August 1987. 
Our experience with tumors metastatic to the liver is 
limited to 7 cases including 2 pancreatic glucagonomas 
(pancreatic origin), 2 intestinal carcinoids, a pancreat!c 
gastrinoma, a small bowel, leiomyosarcoma, and one 
adenocarcinoma of unknown origin. One patient with a 
carcinoid died at 3 months free of tumor and the second 
patient died with tumor at 6 months after transplanta-
tion. The 2 patients with metastatic glucagonomas are 
alive and presumably free of tumor in the liver at 10 and 
Adult Total 
282 (42.3%) 322 (32.2%) 
1 (0.2%) 179 (17.9%) 
161 (24.2%) 161 (16.1%) 
35 (5.3%) 98 (9.8%) 
81 (12.2%) 82 (8.2%) 
38 (5.7%) 42 (4.2%) 
27 (4.1 %) 40 (4.0%) 
13 (2.0%) 20 (2.0%) 
0 15 (1.5%) 
13 (2.0%) 15 (1.5%) 
(0.2%) 8 (0.8%) 
Biliary Atresia (178) 
Inborn Errors (63) 
rates 
most common indications for transplantation 
in children. Cirrhosis includes postnecrotic 
hepatitis and cryptogenic cirrhosis. 
13 months. One of these patients is suspected of still 
having a primary lesion in the pancreas. The patient 
with metastatic small bowel leiomyosarcoma is alive 
and tumor free at 15 months after transplantation. The 
patient with metastatic adenocarcinoma died with tumor 
21 months after transplantation. 
Postnecrotic cirrhosis 
Many patients with postnecrotic cirrhosis have 
benefited from transplantation and the survival rate for 
these patients is 70% at one year and 63.2% at 5 years. 
However, there is a high risk of recurrent infection in B-
virus carriers (HBsAg positive). The one-year survival 
rate for B-virus carriers with chronic aggressive 
hepatitis is 47.8% compared with 77.0% for noncarriers 
(p<0.01) (Fig. 5). In contrast 6 of 7 patients 
transplanted for acute fulminant 8-virus-induced 
hepatic necrosis are surviving 18 months to more than 2 
years after transplantation. 
Primary biliary cirrhosis 
Primary biliary cirrhosis is a disease of unknown 
etiology characterized by jaundice, fatigue, prurititis, os-
teoporosis (hepatic rickets), and progresses slowly to 
liver failure. It most commonly afflicts middle-aged and 
older women. Although the disease is uncommon, it is 
one of the most common indications for liver replace-
ment in adults. Of the 161 patients transplanted for 
primary biliary cirrhosis, 122 are surviving including 85 
......................... 
Primary Biliary Cirrhosis (161) 
Cirrhosis (240) 
Sclerosing Cholangitis (81) 
rates 
most common indications for liver transplanta-
tion in adults. Cirrhosis includes postnecrotic 
cirrhosis and cryptogenic cirrhosis but not 
Laennec's cirrhosis. 
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patients now beyond one year after transplantation. 
Only 2 patients have died more than a year after 
transplantation and so far there are no confirmed cases 
of recurrent primary biliary cirrhosis in the transplanted 
liver. 
HBsAg Negative (243) 
---L--------L _________________ , 
HBsAg Positive (31) 
rates 
transplanted with cirrhosis classified accord-
ing to hepatitis B surface antigen (HBsAg) 
status. A high incidence of recurrent hepatitis 
B after transplantation in HBsAg-positive 
patients resulted in significantly lower survival 
of these patients (p<O.01). 
! 
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Laennec's cirrhosis 
Alcoholic cirrhosis has been a controversial indica-
tion for liver transplantation since the disease is self in-
duced and the risk of recidivism has been thought to be 
high. Furthermore, many patients with advanced al-
coholic liver disease have systemic manifestations of al-
coholism such as neurological degeneration that are ir-
reversible and contraindicate transplantation. However, 
there is no effective alternative therapy available for 
patients with end-stage alcoholic liver disease and 
provided the patient is an acceptable operative risk and 
free of irreversible complications, transplantation may 
be worthwhile. 
Forty-one of the 1,000 patients transplanted in this 
series suffered from alcohol-induced liver disease. 
Twenty-eight are surviving 30 days to one year after 
transplantation. Although our experience to date has 
been encouraging, longer follow-up will be needed to 
determine the effectiveness of liver transplantation and 
the incidence of recidivism in these patients. Peri opera-
tive mortality is less than 10% and therefore these 
patients have not been a prohibitive surgical risk. 
Transplantation in Older Patients 
In the past several years, significant numbers of 
patients over age 60 have been referred for transplanta-
tion, most often with primary biliary cirrhosis or 
postnecrotic cirrhosis. Forty-eight patients over 60 
have been transplanted with 29 surviving. One-year ac-
tuarial survival for patients over 60 is 55.7%. The 2 
oldest patients, a 67-year-old man and a 76-year-old 
woman, both with primary biliary cirrhosis, are well and 
fully rehabilitated 24 and 13 months after transplanta-
tion, respectively. 
One of the most troublesome complications in older 
patients surviving more than 6 months after transplanta-
tion has been debilitating osteoporosis. Many of these 
patients suffer from "hepatic rickets" and osteoporosis 
is further aggravated by the steroid immunosuppres-
sion. It is advantageous in these patients to use as little 
steroid as possible. Fortunately, rejection is often 
easier to control in older patients and it is frequently 
possible to use minimal doses of prednisone. 
IMMUNOLOGICAL FACTORS INFLUENCING 
GRAFT SURVIVAL 
Until recently lack of sufficient case numbers made it 
difficult to assess the importance of immunological fac-
tors, such as ABO blood group differences, preformed 
anti-HLA cytotoxic antibody, or HLA matching on graft 
outcome, in liver transplantation. However, with the in-
creased experience of the last several years it is now 
possible to study these factors. 
ABO Blood Groups 
The ABO blood groups cannot be breached in renal 
transplantation without high risk of hyperacute graft 
rejection. It has been known for many years that 
transplantation of the liver across ABO blood groups 
does not produce hyperacute rejection(5). However, 
we have found that there is a small but significant 
penalty for transplanting the liver across ABO blood 
groups. Graft survival between ABO-identical donor-
recipient pairs is significantly higher than survival of 
grafts between ABO-compatible but nonidentical or 
ABO-incompatible donor-recipient pairs (Fig. 6) (6,7). 
Even when the data are adjusted to remove patients 
transplanted under high risk, urgent conditions, the dif-
ference is still observed (7). 
At the present time, we recommend that ABO-mis-
matched or incompatible grafts only be used when 
transplantation is urgent or donor availability is severely 
limited, such as for small children. \ 
grafts based on donor-recipient ABO com-
patibility. Grafts between ABO-identical donor-
recipient pairs fare better than grafts between 
ABO-mismatched or incompatible pairs. 





PRA <30% (n=67) 
PRA >30% (n=67) 
........ PRA >60% (n=39) 
Positive Cross match (n=62) 
grafts based on recipient panel-reactive an-
tibody (PRA). 7B. Actuarial survival of 
primary liver grafts based on the donor-
specific cytotoxic antibody crossmatch. 
Adapted from Gordon, et aI, Surgery 100:705-
715,1986. 
Preformed Iymphocytotoxic antibody 
High levels of panel reactive antibody (PRA) have 
been associated with increased rates of graft rejection 
in kidney transplantation (8). However, we have not 
demonstrated a similar relationship of PRA to graft sur-
vival in liver transplantation (Fig. 7A). 
A donor-specific Iymphocytotoxic antibody 
crossmatch is routinely performed prior to kidney 
transplantation and a positive cross match is usually 
prohibitive (9,10). Sequential liver-kidney transplants 
have been performed in patients with a strongly positive 
47 
donor-specific antibody crossmatch. When the liver is 
transplanted first in such cases, it is capable of clearing 
enough circulating preformed antibody to protect a kid-
ney immediately transplanted from the same donor 
(11 ). 
There is usually insufficient time to cross match liver 
reCipients prior to transplantation but we have routinely 
collected sera and crossmatched the patients 
retrospectively. A statistical comparison of liver graft 
survival demonstrates no significant difference for 
transplantation between donor-recipient pairs with a 
positive or negative antidonor lymphocyte antibody 
crossmatch (Fig. 78) (12). It is likely that hyperacute 
rejection of the liver does in fact occur in certain uncom-
mon and still poorly defined circumstances but it cannot 
be reliably predicted by the conventional antibody 
crossmatch. Additional studies are under way to deter-
mine if there are selected specificities and target cells 
which can predict antibody-mediated rejection of the 
liver. 
HLA matching 
Liver transplantation is performed without regard to 
HLA matching and therefore analysis of the effect of 
HLA antigens can only be done retrospectively. In any 
single series the number of high grade matches is rela-
tively small. Nevertheless, some interesting trends are 
suggested in our first analysis of this series. 
Grafts transplanted with no mismatch at the A locus 
have not done as well (p<0.03) as grafts transplanted 
with a one or 2 HLA-A mismatches (Fig. 8) (13). Similar 
data for matching at HLA-DR approaches statistical sig-
nificance (p = 0.08) (Fig. 9). A longer follow-up of an 
even larger, multicenter series of patients is necessary 
to confirm these initial observations. 
It has been suggested that this paradoxical effect of 
HLA matching might represent a dualistic effect of HLA 
antigens involving self-recognition (MHC restricted 
processing of autoantigens) on the one hand and al-
loreactivity on the other. Some of the more common 
causes of end-stage liver disease, such as primary 
biliary cirrhosis, sclerosing cholangitis, and viral 
hepatitis, involve immune mechanisms which might be 
facilitated by HLA matches. However, we have no 
direct evidence that disease recurrence facilitated by 
HLA matching is responsible for graft loss. 
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o Mismatch (42) 
1 Mismatch (210) 
based on number of mismatches at the HLA-A 
locus. The long-term sUNival of grafts with 
zero mismatch at HLA-A was significantly less 
(p<0.03) than sUNival of grafts with one or 2 
mismatches. Adapted from Markus et aI, 
Transplant Proc, in press. 
Liver transplantation is now the preferred treat-
ment for many diseases leading to end-stage liver 
disease. Transplantation for cancer has been disap-
pointing and there is a significant recurrence rate 
after transplantation in hepatitis B-virus carriers. Ad-
ditional strategies will have to be developed if we are 
Figure 9. liver 
based on number of mismatches at the HLA-
DR locus. The long-term sUNival of grafts 
with zero mismatch at HLA-DR was less than 
sUNival of grafts with one or two mismatches, 
but the differences are not statistically sig-
nificant (p = 0.08). Adapted from Markus et aI, 
to improve the results of transplantation for these 
patients. The role of immunological factors in liver 
transplantation continues to reveal significant dif-
ferences from their role in renal transplantation and 
will continue to be an interesting area of study for 
years to come. 
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